Now I have all the information needed to produce the final consolidated review. Let me write it.

## Summary

GANDALF proposes a generative framework for augmenting sparse patient genomic mutation data in drug response prediction (DRP), leveraging larger labelled cell-line datasets. The method uses denoising diffusion probabilistic models (DDPMs) with domain alignment, cross-attention, and multi-task pseudo-labeling to generate "patient-like" samples and assign drug response labels, explicitly modeling the distributional differences between cell lines and patients that prior methods (including WISER) neglect. Experiments on multiple public patient datasets (TCGA, CBIO, Moores) show GANDALF achieving the best AUROC on 4 out of 5 benchmark drugs and improvements over SOTA methods.

## Strengths

1. **First generative augmentation framework that explicitly models domain differences in DRP.** The paper identifies that prior methods either augment in a shared representation space (losing patient-specific characteristics) or, like WISER, augment via pseudo-labeling without accounting for $P(X_c) \neq P(X_p)$ and $domain(y_c) \neq domain(y_p)$. GANDALF's pipeline — domain-specific DDPMs with CORAL alignment, cross-attention to preserve source information, and multi-task learning with separate prediction heads for AUDRC (regression) and RECIST (classification) — is a novel synthesis that directly targets this gap (Sections 3.2.1–3.2.3).

2. **Outperforms SOTA methods on multiple patient-level benchmarks.** In Table 1, GANDALF achieves the best AUROC on 4 of 5 drugs (Flu, Gem, Pac, Tem) and best AUPRC on 3 of 5, with improvements up to 10.96% over the next-best method. It is tested against 6 recent baselines (DruID, PREDICT-AI, drug2tme, PANCDR, CODE-AE, WISER) across three patient data sources.

3. **Ablation study validates each architectural component.** Table 2 shows that removing the MTL head, cross-attention KL divergence loss, or transformer encoder each degrades both AUROC and AUPRC, confirming that the full design drives performance. The "W/O transformer" condition (using the same 7776-dim binary input as baselines) partially disentangles the augmentation benefit from the representation advantage.

4. **Handles variable-length mutation profiles natively.** Unlike most SOTA methods that require fixed 7776-dim binary vectors, GANDALF uses a pretrained transformer encoder to process varying numbers of mutations per sample, which is a practical advantage for clinical sequencing data where mutation counts vary widely.

5. **Empirically outperforms naive perturbation and majority-vote pseudo-labeling.** GANDALF beats Gaussian noise perturbation (+21%) and majority-vote pseudo-labeling (+2.5%), providing concrete evidence that its combined generative augmentation and domain-aware label assignment strategy is effective (Sections 4.4–4.5, Table 2).

## Weaknesses

### Fatal

None.

### Major

1. **No measures of statistical uncertainty reported.** Tables 1 and 2 present point estimates with no standard deviations, confidence intervals, or significance tests. Given the small patient dataset (669 samples across 56 drugs, with the 5 evaluated drugs being the only ones with samples in all 3 folds), per-drug sample sizes are likely on the order of dozens. Without variance estimates, the reported improvements (including the headline 10.96% figure) could be within random variation. This is the most significant weakness — it makes the evaluation difficult to interpret as strong evidence for the method.

2. **Input representation confound in main comparison.** GANDALF uses a transformer encoder with a learned 23-dim mutation embedding pretrained on PFS prediction, while most baselines (DruID, drug2tme, PANCDR, CODE-AE, WISER) receive a 7776-dim sparse binary vector. Only PREDICT-AI shares a comparable input representation. This gives GANDALF an advantage independent of its augmentation pipeline. The "W/O transformer" ablation partially addresses this, but Table 1's main comparison conflates the augmentation benefit with the representation advantage. The paper would be stronger if all methods were compared under the same input representation, or if the augmentation benefit were isolated more cleanly.

3. **Concerns about baseline tuning quality.** The critic reports that WISER achieves only 0.260 AUROC on Cisplatin, far below random chance. If accurate, this suggests the baseline implementations may not be well-tuned for this setting, undermining the claim that GANDALF outperforms "SOTA" methods in a fair comparison. The paper does not discuss anomalously low baseline performance or verify that baselines are optimally configured.

### Minor

4. **Evaluation limited to 5 of 56 drugs.** The paper justifies this (drugs with samples in all 3 test folds), which is a reasonable methodological choice. However, it does not report how many patient samples are available per drug (even for the 5 evaluated drugs), nor does it discuss the limitation in the conclusions section — this scope restriction should be acknowledged prominently given the claims about generalization.

5. **Key hyperparameters absent from main text.** Values for the VAE latent dimensionality ($l$), number of diffusion timesteps ($T$), and confidence thresholds ($t_u$, $t_l$) are not given in the main text. While they may appear in the algorithm box or appendix, the main text should at least summarize key settings for a self-contained read.

6. **Transformer freezing not discussed or justified.** The paper states "Parameters of $T_e$ are frozen for training" (line 166) without discussing why fine-tuning on the DRP task would not be beneficial. A brief justification would address this.

### Trivial

None beyond those listed above.

## Nice-to-Haves

- Report per-drug sample sizes to contextualize the data scarcity problem.
- Add error bars, confidence intervals, or significance tests to all key tables.
- Include an experiment where all baselines use the same input representation (e.g., both GANDALF and baselines use the transformer embeddings, or GANDALF uses the 7776-dim vector for the final classifier while the generative module still uses transformers), to isolate the augmentation benefit.
- Show qualitative analysis of generated samples (e.g., PCA, mutation frequency comparisons) to demonstrate that $X_{aug}$ indeed resembles $P(X_p)$.
- Report computational cost (GPU hours) to help assess practical feasibility.

## Removed Points

These points were raised by reviewers but are removed (with justification) to prevent noise:

- **"Novelty framed too broadly / overstated claim of being first"** — The claim is "first to tackle…through a novel data augmentation approach" (line 25). The paper clearly acknowledges WISER's pseudo-labeling approach and distinguishes GANDALF by explicitly modeling domain differences ($P(X_c) \neq P(X_p)$, $domain(y_c) \neq domain(y_p)$). The framing is defensible and the distinction is substantiated.
- **"Naive Gaussian noise comparison not meaningful"** — This is a legitimate baseline: it demonstrates why naive label-preserving perturbation fails for genomic DRP, directly supporting the paper's motivation. Removing it would weaken the evaluation.
- **"Limited to 5 drugs without justification"** — The paper *does* justify the choice: "drugs with samples available in all 3 test folds" (line 264). This is a standard experimental design choice. The limitation itself is real (kept above as Minor #4), but the claim that it's unjustified is incorrect.
- **"Missing appendix content / reproducibility details"** — The appendix is stripped by the PDF parser. The original submission includes it. Criticizing the absence of content that likely exists in the appendix is not valid.
- **"Missing qualitative analysis of generated samples"** — The paper states "We examined the quality of the generated samples by comparing the distributions against the original patient data" (line 303). Results may be in the appendix.

## Novel Insights

The reviews surface a genuine tension in the paper: GANDALF's strength is its architectural intricacy (domain-specific DDPMs, cross-attention, multi-task pseudo-labeling) which directly targets a real and underappreciated problem — that prior DRP augmentation methods ignore domain shift in both data distribution and label type. However, the same complexity makes clean evaluation difficult. The ablation helps but is itself missing error bars. The most actionable insight from combining the reviews is that the paper needs a much tighter evaluation design (controlled input representation, statistical uncertainty, per-drug sample transparency) to match the elegance of its method. The core idea is strong; the evidence for it is currently not commensurate.

## Suggestions

1. **Add error bars and significance tests.** Report mean ± std across the 3 test folds for all metrics in Tables 1 and 2. Without these, the central claim of improvement over SOTA is not statistically grounded.
2. **Isolate the augmentation benefit from the representation advantage.** A clean experiment would be: run GANDALF's augmentation pipeline using the 7776-dim input for the downstream classifier (while keeping transformers for generation) and compare against baselines also using 7776-dim input. Alternatively, provide all baselines with the same transformer embeddings GANDALF uses.
3. **Report per-drug sample sizes** for the 5 evaluated drugs and discuss how data scarcity varies across them.
4. **Verify baseline configurations.** Ensure all baselines are well-tuned (e.g., WISER should not be below chance on any drug). Report tuning procedure and discuss any drugs where baselines struggle.
5. **Acknowledge the evaluation scope explicitly** in the conclusions as a limitation.

## Score and Decision

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Reject</decision>